Although early studies indicated that PD-L1 expression may be a predictable biomarker for therapeutic response to anti-PD-1 antibodies, only a subset of patients with NSCLC responded to PD-1 blockade, indicating the genetic background of the cancer patients may be a key determinant of response to this therapy. The gene discussed is PDCD1; the disease is cancer.